Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.
A team of researchers has developed a "gut-on-chip" (a miniature model of the human intestine on a chip-sized device) capable ...
5h
In the ongoing battle against triple negative breast cancer, Vanderbilt researchers have uncovered a promising non-invasive ...
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. | Bristol Myers Squibb is striking out ...
Bristol Myers Squibb's Opdualag (relatlimab/Opdivo) fails Phase 3 melanoma trial, adding to mixed results for LAG-3/PD-1 targeting immunotherapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback